HOME >> MEDICINE >> NEWS
First medication to target PCP addiction is reported by Arkansas researchers

Animal studies by researchers at the University of Arkansas for Medical Sciences (UAMS) used an antibody-based drug to provide immediate protection against the chronic abuse of phencyclidine (PCP). The studies mark the first time that a long-acting treatment has been developed to block or reduce the psychoactive effects of PCP in drug addicts, according to UAMS scientist S. Michael Owens, Ph.D. In earlier studies, he used a smaller fragment of the antibody to treat drug overdose.

Owens presented his findings here today at the national meeting of the American Chemical Society, the world's largest scientific society.

Owens said his new technique uses monoclonal antibodies-identical copies of animal antibodies cloned and reproduced in the laboratory-to prevent or slow the entry of PCP into the brain, where it produces its pleasurable effects. The ability to create huge quantities of these antibodies makes it possible to administer a very large dose in a single injection. In the animal studies, just one injection curbed the effects of PCP for at least two weeks-a period equivalent to one to two months in humans, Owens said.

This fast-acting therapy could make a profound difference in the way PCP addicts are treated, enabling doctors to offer addicts an effective anti-addiction medication that works immediately. By contrast, antibody-based approaches to creating vaccines entail weeks of waiting before benefits appear, Owens said.

PCP triggers hallucinations, psychotic behavior, violence, and even self-destruction.

In a 1997 NIDA survey of high school seniors, more than two percent of the students said they had used PCP in the preceding 30 days. "Young people are attracted to PCP even though they know how dangerous it is, because it is inexpensive and because it produces euphoria, hallucinations and a feeling of superhuman strength," said Owens.

The UAMS research is supported by grants from the National Institute for Drug Ab
'"/>

Contact: Charmayne Marsh
y_marsh@acs.org
202-872-4445
American Chemical Society
24-Aug-1999


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
Cached News: